search for



Cross mark




View (252) Download (679) CrossRef (1)
Behavioral Therapy and Pharmacotherapy for Relapse Prevention in Abstinent Smokers: Korea Preventive Services Task Force Guidance
J Korean Soc Res Nicotine Tob 2021; 12(1): 8-15
Published online June 15, 2021
© 2021 The Korean Society for Research on Nicotine and Tobacco.

Naae Lee1, Eon Sook Lee2, Jae Moon Yun3, Cheol Min Lee4, Seung-Won Oh4, Younglee Choi5, Belong Cho3*, Korea Preventive Services Task Force

1Department of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, 2Department of Family Medicine, Ilsan-Paik Hospital, Inje University, Goyang, 3Department of Family Medicine, Seoul National University Hospital, 4Department of Family Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 5Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea
Correspondence to: 議곕퉬猷
꽌슱븰援먮퀝썝 媛젙쓽븰怨
怨듬룞 젣1 옄.
吏덈퀝삁諛⑹꽌鍮꾩뒪쐞썝쉶 紐낅떒: 씠醫낃뎄(꽌슱븰援 쓽怨쇰븰, 쐞썝옣) 源쁽李(뿰꽭븰援 쓽怨쇰븰), 諛뺣퀝二(꽌슱븰援 쓽怨쇰븰), 議곗쥌씗(꽌슱듅蹂꾩떆 遺곷蹂묒썝 蹂닿굔쓽猷뚮났吏넻빀꽱꽣), 議곗젙吏(븳由쇰븰援 쓽怨쇰븰), 議곗꽦씪(꽌슱븰援 蹂닿굔븰썝), 源닔쁺(븳由쇰븰援 쓽怨쇰븰), 씠꽍援(異⑸궓븰援 쓽怨쇰븰), 源쁺옱(援먮낫깮紐낅냽쓽썝), 엫쁽슦(媛넧由븰援 쓽怨쇰븰), 議곕퉬猷(꽌슱븰援 쓽怨쇰븰), 떊듅닔(븘二쇰븰援 쓽怨쇰븰), 源嫄댁뿽(寃쎈턿븰援 쓽怨쇰븰), 씠泥좎<(꽌슱븰援 뼵濡좎젙蹂댄븰怨)
Received February 2, 2021; Revised May 20, 2021; Accepted May 22, 2021.
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, dis-tribution, and reproduction in any medium, provided the original work is properly cited.
Background: This paper presents the Korea Preventive Services Task Force (KPSTF) guidance on behavioral and pharmacotherapy for relapse prevention in abstinent smokers.
Methods: Evidence was evaluated at the evidence-based practice center of the KPSTF to develop KPSTF guidance through a rapid systematic review of both behavioral and pharmacologic intervention. Subsequently, evidence level and recommendation grade were examined in accordance with the KPSTF Manual for Public Health Guidance. Consensus on the recommendation grade determined by nine experts was obtained using a modified Delphi method to evaluate the effect size, priority, resources, feasibility, health equity, and reliability of the values and preferences.
Results: This guidance applies to smokers who successfully quit smoking over 24 h on their own (unassisted abstainers), who forcibly quit because of pregnancy or hospitalization, or who quit by participating in a smoking cessation program (assisted abstainers).
Conclusion: The KPSTF does not recommend providing behavioral therapy for abstinent smokers for relapse prevention (Recommendation grade: D, evidence level: high). Instead, it recommends pharmacotherapy, albeit with weak intensity (Recommendation grade: B evidence level: high). A significant effect was confirmed in the relapse prevention intervention in pharmacotherapy, but the effect was not large (RR [95% CI]: 1.15 [1.05, 1.26], I2=40.71%). This recommendation was developed on the basis of diverse drug and foreign data, so evidence should be obtained through randomized clinical trials. However, we cannot conclude if it will have the same effect in Korea. Therefore, a sufficient number of domestic studies and long-term follow-up are required in the future to verify the relapse prevention intervention.
Keywords : Behavioral therapy; Pharmacotherapy; Relapse prevention; Smoking cessation; Guidance
  1. Korea Disease Control and Prevention Agency, Korea Preventive Services Task Force. Community Health Programs for Diabetes Prevention and Management. 2017-2019 Korea Preventive Services Task Force Guidance; 2020.
  2. Korea Disease Control and Prevention Agency, Korea Preventive Services Task Force, National Evidence-based Healthcare Collaborating Agency. Manual of Korea Preventive Services Task Force Guidance Development; 2017.
  3. European Network for Smoking and Tobacco Prevention. 2018 Guidelines for treating tobacco dependence:
  4. Centers for Disease Control and Prevention. Fast Facts (2020, May 21). Available from [Accessed 2020 Oct 27].
  5. U.S. Department of Health and Human Services. The Health Con-sequences of Smoking: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2020.
  6. World Health Organization. Tobacco [Internet].
  7. Wang R, Jiang Y, Yao C, Zhu M, Zhao Q, Huang L, et al. Prevalence of tobacco related chronic diseases and its role in smoking cessation among smokers in a rural area of Shanghai, China: a cross sectional study. BMC public health 2019; 19(1): 753.
  8. Jacob L, Freyn M, Kalder M, Dinas K, Kostev K. Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: a retrospective study of 422,010 patients followed for up to 30 years. Oncotarget 2018; 9(25): 17420-9.
  9. Reitsma MB, Fullman N, Ng M, Salama JS, Abajobir A, Abate KH, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. The Lancet 2017; 389(10082): 1885-906.
  10. Korea Health Statistics 2017. Korea Disease Control and Prevention Agency. 2018.
  11. Komiyama M, Takahashi Y, Tateno H, Mori M, Nagayoshi N, Yonehara H, et al. Support for Patients Who Have Difficulty Quitting Smoking: A Review. Internal Medicine 2019; 58(3): 317-20.
  12. McDermott MS, Marteau TM, Hollands GL, Hankins M, Aveyard P. Change in anxiety following successful and unsuccessful attempts at smoking cessation: cohort study. The British Journal of Psychiatry 2013; 202(1): 62-7.
  13. Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, et al. Impact of prior nicotine replacement therapy on smoking cessation efficacy. Am J Health Behav. 2002; 26(3): 213-20.
  14. Smoking Cessation. A Report of the Surgeon General. Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2020.
  15. Livingstone륛anks J, Norris E, Hartmann륛oyce J, West R, Jarvis M, Chubb E, et al. Relapse prevention interventions for smoking cessation. Cochrane Database of Systematic Reviews 2019; (10).
  16. Tonstad S, T첩nnesen P, Hajek P, Williams KE, Biling CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296(1): 64-71.
  17. Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction 2007; 102(8): 1292-302.
  18. Kim S, Shin S, Seo H, Lee S. Guidance for undertaking rapid systematic review. Seoul, Korea: Korea Preventive Services Task Forces; 2017.
  19. Lee N, Lee ES, Yun JM, Lee CM, Oh SW, Choi Y, et al. Behavioral Therapy and Pharmacotherapy for Relapse Prevention in abstinent smokers: A Rapid Review and Meta-analysis for the Korea Preventive Service Task Force. Osong public health and research perspectives 2021; j.phrp.2021.0017. Epub 2021 May 27.
  20. Hajek P, Stead LF, West R, Jarvis M, Hartmann-Boyce J, Lancaster Tim. Relapse Prevention Interventions for Smoking Cessation. Cochrane Database of Systematic Reviews 2013; (8).
  21. Agboola S, McNeill A, Coleman T, Bee JL. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105(8): 1362-80.
  22. Siu AL. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: US Preventive Services Task Force recommendation statement. Annals of internal medicine 2015; 163(8): 622-34.